Cannabinoids in MS - Are we any closer to knowing how best to use them?

Multiple Sclerosis

Volumn 12, Issue 5, 2006, Pages 523-525

  Bowling, Alan ^a  

^a Rocky Mountain MS Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ALCOHOL; ANANDAMIDE; ANTICONVULSIVE AGENT; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; ENDOCANNABINOID; NEUROTRANSMITTER RECEPTOR; PLACEBO; TETRAHYDROCANNABINOL DERIVATIVE; CANNABINOID; CANNABINOID RECEPTOR;

ALCOHOL CONSUMPTION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEALTH SURVEY; HUMAN; LONG TERM CARE; MEDICAL LITERATURE; MEDICAL RESEARCH; MOUTH DISEASE; MULTIPLE SCLEROSIS; NAUSEA; NERVE CONDUCTION; NERVE EXCITABILITY; PHYSICAL DISABILITY; PROTEIN ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEIZURE; TREATMENT OUTCOME; METABOLISM; NOTE; PHYSIOLOGY;

CANNABINOIDS; HUMANS; MULTIPLE SCLEROSIS; RECEPTORS, CANNABINOID;

EID: 34250658890     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458506072514     Document Type: Editorial

References (13)

1. Iversen L. Cannabis and the brain. Brain 2003; 126: 1252-1270.
2. Bowling AC. Worthless weed or pot of gold? Int J MS Care 2003; 5: 138-166.
3. Katona S, Kaminski E, Sanders H, Zajicek J. Cannabinoid influence on cytokine profile in multiple sclerosis. Clin Exper Immunol 2005; 140: 580-585.
4. Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E. Cannabis use in patients with multiple sclerosis. Mult Scler 2006; 5: 646-651.
5. Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms of multiple sclerosis. Mult Scler 2006; 12: 639-645.
6. Barnes MP. Sativex: clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin Pharmacother 2006; 12: 607-615.
7. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME. Patterns of cannabis use among patients with multiple sclerosis. Neurol 2004; 62: 2098-2100.
8. Smith PF. Cannabinoids as potential anti-epileptic drugs. Curr Opin Investig Drugs 2005; 6: 680-685.
9. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomized placebo-controlled trial. Lancet 2003; 362: 1517-1526.
10. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomized placebo-controlled trial (CAMS-LUTS). Int Urogynecol J 2006; published online March 22, 2006.
11. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psych 2005; 76: 1664-1669.
12. Witting A, Chen L, Cudaback E, Straiker A, Walter L, Rickman B, et al. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection. Proc Natl Acad Sci USA 2006; 103: 6362-6367.
13. Killestein J, Hoogervorst ELJ, Reif M, Blauw B, Smits M, Uitdehaag BMJ, et al. Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis. J Neuroimmunol 2003; 137: 140-143.